| Description | D-erythro-Sphingosine (trans-4-Sphingenine) is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator |
| In vitro | D-erythro-Sphingosine inhibits protein kinase C in vitro[1]. D-erythro-Sphingosine has been shown to inhibit protein kinase C, which affects cell regulation and several signal transduction pathways, and exhibits antitumor promoter activities in various mammalian cells[2]. |
| Target activity | p32:8 μM (EC50) |
| Synonyms | trans-4-Sphingenine, erythro-C18-Sphingosine, Erythrosphingosine, 鞘氨醇, D-鞘氨醇 |
| molecular weight | 299.49 |
| Molecular formula | C18H37NO2 |
| CAS | 123-78-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 250 mg/mL (834.75 mM) |
| References | 1. Khan W A , Dobrowsky R , El T S , et al. Protein kinase C and platelet inhibition by D-erythro-sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation.[J]. Biochemical & Biophysical Research Communications, 1990, 172(2):683-691. 2. Pham V T , Joo J E , Tian Y S , et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-sphingosine[J]. Archives of Pharmacal Research (Seoul), 2007, 30(1):22-27. |